$74.14 -$1.75 (-2.3%)

04:15 PM EDT on 07/10/20

Biohaven Pharmaceutical (NYSE:BHVN)

CAPS Rating: No stars

Current Price $74.14 Mkt Cap $4.3B
Open $75.79 P/E Ratio 0.00
Prev. Close $74.14 Div. (Yield) $0.00 (0.0%)
Daily Range $73.50 - $75.81 Volume 82,405
52-Wk Range $26.56 - $78.75 Avg. Daily Vol. 859,729

Caps

How do you think NYSE:BHVN will perform against the market?

Add Stock to CAPS Watchlist

All Players

7 Outperform
3 Underperform
 

All-Star Players

2 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:BHVN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mdriver78 (72.36)
Submitted February 12, 2020

Shares of Biohaven took an 8% tumble this week as the company announced a failure in a Phase 3 trial.The drug, troriluzole, was set up compared with placebo in patients with generalized anxiety disorder. Unfortunately, it did not prove it was better… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NYSE:BHVN VS S&P 500 (SPY)

NYSE:BHVN Summary

Fools bullish on NYSE:BHVN are also bullish on:

Fools bearish on NYSE:BHVN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BHVN.

Recs

1
Member Avatar mdriver78 (72.36) Submitted: 2/12/2020 11:46:01 AM : Outperform Start Price: $52.22 NYSE:BHVN Score: +42.94

Shares of Biohaven took an 8% tumble this week as the company announced a failure in a Phase 3 trial.

The drug, troriluzole, was set up compared with placebo in patients with generalized anxiety disorder. Unfortunately, it did not prove it was better at reducing anxiety.

While unfortunate, the main event remains in view for us, and it will be the major driver for BHVN shares this year.
Should not have to wait long for big regulatory and clinical catalysts for rimegepant, the company’s migraine drug.
Biohaven plans to file the drug with the FDA for acute migraine treatment by the end of next quarter. Moreover, data for rimegepant as a migraine preventative are expected this quarter from a different Phase 3 trial.

Rimegepant was recently named by market analytics firm Clarivate Analytics as one of the new drugs expected to enter the market this year that have blockbuster potential.

Migraines affect some 40 million Americans, and the standard of care hasn’t changed in over two decades. Rimegepan’s mechanism of action, which causes inflammation reduction, reduced vascular dilation and pain signal inhibition, brings a new tool for dealing with painful, incapacitating migraines.

Marketing a drug that grosses over $1 billion per year will represent a big success for Biohaven and could drive valuation to a multiple of its current $2.8 billion market cap. That all starts with a potential approval by the FDA, with a PDUFA date scheduled by the end of June.

Leaderboard

Find the members with the highest scoring picks in BHVN.

Score Leader

HDTVBG

HDTVBG (< 20) Score: +150.86

The Score Leader is the player with the highest score across all their picks in BHVN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Custom63Willys < 20 2/1/2019 Outperform 1Y $38.78 +91.18% +17.65% +73.54 0 Comment
jeepdrew222 83.10 2/1/2019 Outperform 5Y $38.78 +91.18% +17.65% +73.54 0 Comment
XMFHaen 58.54 2/12/2020 Outperform 1Y $44.83 +65.38% -5.72% +71.11 0 Comment
portefeuille 99.10 10/31/2019 Outperform 5Y $46.76 +58.55% +4.57% +53.98 0 Comment
mdriver78 72.36 12/19/2019 Outperform 5Y $52.22 +41.98% -0.96% +42.94 1 Comment
ssfinanchill 42.08 4/1/2019 Outperform 3M $52.28 +41.81% +11.63% +30.18 0 Comment
macattack003 62.13 4/16/2019 Outperform 3W $59.06 +25.53% +9.24% +16.30 0 Comment
justaboutperfect 60.99 6/23/2020 Underperform 5Y $75.12 -1.30% +1.44% +2.75 0 Comment
chammond55 98.67 5/4/2020 Underperform 3M $46.72 +58.69% +13.24% -45.45 0 Comment
BigCaps18 42.32 8/16/2019 Underperform 5Y $37.87 +95.78% +10.87% -84.90 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BHVN.